These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1196 related articles for article (PubMed ID: 31690181)

  • 1. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
    Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
    Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy.
    Lin S; Huang G; Cheng L; Li Z; Xiao Y; Deng Q; Jiang Y; Li B; Lin S; Wang S; Wu Q; Yao H; Cao S; Li Y; Liu P; Wei W; Pei D; Yao Y; Wen Z; Zhang X; Wu Y; Zhang Z; Cui S; Sun X; Qian X; Li P
    MAbs; 2018; 10(8):1301-1311. PubMed ID: 30204048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
    Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
    J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse.
    Ashizawa T; Iizuka A; Nonomura C; Kondou R; Maeda C; Miyata H; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Katano I; Ito M; Akiyama Y
    Clin Cancer Res; 2017 Jan; 23(1):149-158. PubMed ID: 27458246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
    Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
    J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
    Antonios JP; Soto H; Everson RG; Moughon D; Orpilla JR; Shin NP; Sedighim S; Treger J; Odesa S; Tucker A; Yong WH; Li G; Cloughesy TF; Liau LM; Prins RM
    Neuro Oncol; 2017 Jun; 19(6):796-807. PubMed ID: 28115578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
    Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
    Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
    Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
    J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An improved cell line-derived xenograft humanized mouse model for evaluation of PD-1/PD-L1 blocker BMS202-induced immune responses in colorectal cancer.
    Shang P; Yu L; Cao S; Guo C; Zhang W
    Acta Biochim Biophys Sin (Shanghai); 2022 Oct; 54(10):1497-1506. PubMed ID: 36269133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity.
    Kotanides H; Li Y; Malabunga M; Carpenito C; Eastman SW; Shen Y; Wang G; Inigo I; Surguladze D; Pennello AL; Persaud K; Hindi S; Topper M; Chen X; Zhang Y; Bulaon DK; Bailey T; Lao Y; Han B; Torgerson S; Chin D; Sonyi A; Haidar JN; Novosiadly RD; Moxham CM; Plowman GD; Ludwig DL; Kalos M
    Cancer Immunol Res; 2020 Oct; 8(10):1300-1310. PubMed ID: 32873605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy.
    Zhai W; Zhou X; Zhai M; Li W; Ran Y; Sun Y; Du J; Zhao W; Xing L; Qi Y; Gao Y
    Sci China Life Sci; 2021 Apr; 64(4):548-562. PubMed ID: 32737851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
    Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
    J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triptolide suppresses oral cancer cell PD-L1 expression in the interferon-γ-modulated microenvironment in vitro, in vivo, and in clinical patients.
    Kuo CS; Yang CY; Lin CK; Lin GJ; Sytwu HK; Chen YW
    Biomed Pharmacother; 2021 Jan; 133():111057. PubMed ID: 33378962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
    Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
    Lee MY; Robbins Y; Sievers C; Friedman J; Abdul Sater H; Clavijo PE; Judd N; Tsong E; Silvin C; Soon-Shiong P; Padget MR; Schlom J; Hodge J; Hinrichs C; Allen C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
    Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
    Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models.
    Pyo KH; Kim JH; Lee JM; Kim SE; Cho JS; Lim SM; Cho BC
    Lung Cancer; 2019 Jan; 127():112-121. PubMed ID: 30642538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.